ct041
Cell therapyexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 25, 2020 (NCT04404595)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Claudin-18Immunity, passive
CLDN18 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06857786 | Phase 1 | Mar 10, 2025 | Peking University |
| NCT05911217 | Phase 1 | Jul 11, 2023 | CARsgen Therapeutics, Ltd., Fudan University |
| NCT04581473 | Phase 1/Phase 2 (Phase 2) | Oct 23, 2020 | CARsgen Therapeutics, Ltd., Chinese Academy of Medical Sciences, Fudan University |
| NCT04404595 | Phase 1 | Sep 25, 2020 | CARsgen Therapeutics, Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CARsgen Therapeutics, Ltd. | For profit | 3 | 3 | 2 | 2020 |
| Fudan University | Academic/Hospital | 2 | 0 | 2 | 2020 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1